Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960568 · ClinicalTrials.gov registry record · Phase 1
Genetic Variability in CYP2D6 in U.S Active Duty Population
A Phase 1 study, sponsored by Walter Reed Army Institute of Research (WRAIR).
- Completed
- Registry status
- Phase 1
- Development phase
- 550
- Enrollment target
NCT02960568: Completed Phase 1 study, sponsored by Walter Reed Army Institute of Research (WRAIR).
NCT02960568 is a Phase 1 study that has completed, run by Walter Reed Army Institute of Research (WRAIR). The registered enrollment target is 550 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (817% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960568, a Phase 1 study, has completed, sponsored by Walter Reed Army Institute of Research (WRAIR).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 550 participants
- Enrollment target
Study Summary
The investigator proposes to 2D6 (Cytochrome P-450 Isoenzyme 2D6) genotype and phenotype a group of active duty service members and assess the effects on primaquine metabolism.
Primary Outcome
Genotyping of CYP2D6 alleles will be analyzed by a multiplexed cytometric bead array assay, Luminex xTAG® CYP2D6 Kit v3 (Austin, TX) which allows for detection of the 16 major alleles of 2D6 in the United States: 1,2,3,4,5,6,7,8,9,10,11,15, 17,29, 35,41. Subjects will then be categorized by CYP2D6 phenotype according to standard definitions of enzyme metabolic activity of specific 2D6 alleles using the published activity score model: AS Model A (1): "poor" (PM), "intermediate" (IM), "extensive"
Interventions
- DRUG Primaquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2016-01-08 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
What the finished NCT02960568 record still lists
NCT02960568 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (817% higher).
The record links to 0 conditions, and to 1 intervention - of which Primaquine is the first listed.
NCT02960568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02960568 about?
NCT02960568 is a clinical study titled "Genetic Variability in CYP2D6 in U.S Active Duty Population". The investigator proposes to 2D6 (Cytochrome P-450 Isoenzyme 2D6) genotype and phenotype a group of active duty service members and assess the effects on primaquine metabolism.
What is the current status of trial NCT02960568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 550 participants. The study started on 2016-01-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02960568?
The interventions under investigation include: Primaquine (DRUG).
Who is sponsoring clinical trial NCT02960568?
This trial is sponsored by Walter Reed Army Institute of Research (WRAIR), which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02960568's enrollment target sits among peer trials
550 35th of 2000 higher than 1,966 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI